Skip to main content
Top
Published in: BMC Public Health 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand

Authors: Chayanis Kositamongkol, Sukrit Kanchanasurakit, Euarat Mepramoon, Pattarawalai Talungchit, Pattama Chaopotong, Kirati Kengkla, Thanet Chaisathaphol, Surasak Saokaew, Pochamana Phisalprapa

Published in: BMC Public Health | Issue 1/2023

Login to get access

Abstract

Introduction

Cervical cancer ranks as the third most prevalent cancer among women in Thailand. However, the effectiveness of cervical cancer screening programs is limited by several factors that impede the screening rate. The utilization of self-collected samples for screening purposes has the potential to alleviate barriers to screening in Thai women. This study assessed the cost-utility and budget impact of implementing cervical cancer screening using self-collected samples for human papillomavirus (HPV) deoxyribonucleic acid (DNA) testing in Thailand.

Materials and methods

We employed a decision tree integrated with a Markov model to estimate the lifetime costs and health benefits associated with the cervical cancer screening program for women aged 25–65. The analysis was conducted from a societal perspective. Four screening policy options were compared: (1) additional self-collected samples for HPV DNA testing, (2) clinician-collected samples for HPV DNA testing only, (3) clinician-collected samples for cytology test (i.e., status quo), and (4) no screening. The model inputs were based on unvaccinated women. The screening strategies and management in those with positive results were assumed followed to the Thai clinical practice guideline. Costs were reported in 2022 Thai baht. Sensitivity analyses were conducted. The ten-year budget impacts of the additional self-collected samples for HPV DNA testing were calculated from a payer perspective.

Results

All screening policies were cost-saving compared to no screening. When comparing the additional self-collected samples for HPV DNA testing with the clinician-collected samples policy, it emerged as the dominant strategy. The incremental benefit in cervical cancer prevention achieved by incorporating self-collected samples for screening was observed at any additional screening rate that could be achieved through their use. Sensitivity analyses yielded consistently favorable results for the screening policies. The average annual budget impact of the additional self-collected samples for screening policy amounted to 681 million Thai baht. This budget allocation could facilitate cervical cancer screening for over 10 million women.

Conclusions

An addition of self-collected samples for HPV DNA testing into the cervical cancer screening program is cost-saving. The benefits of this screening policy outweigh the associated incremental costs. Policymakers should consider this evidence during the policy optimization process.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rimel BJ, Kunos CA, Macioce N, Temkin SM. Current gaps and opportunities in screening, prevention, and treatment of Cervical cancer. Cancer. 2022;128(23):4063–73.CrossRefPubMed Rimel BJ, Kunos CA, Macioce N, Temkin SM. Current gaps and opportunities in screening, prevention, and treatment of Cervical cancer. Cancer. 2022;128(23):4063–73.CrossRefPubMed
2.
go back to reference World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. 2 ed. Geneva: World Health Organization; 2021. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. 2 ed. Geneva: World Health Organization; 2021.
3.
go back to reference World Health Organization. The Global Cancer Observatory: Thailand. The Global Cancer Observatory. 2020. World Health Organization. The Global Cancer Observatory: Thailand. The Global Cancer Observatory. 2020.
4.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
5.
go back to reference Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni AS, et al. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. PLoS ONE. 2021;16(2):e0245894.CrossRefPubMedPubMedCentral Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni AS, et al. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. PLoS ONE. 2021;16(2):e0245894.CrossRefPubMedPubMedCentral
6.
go back to reference Ploysawang P, Rojanamatin J, Prapakorn S, Jamsri P, Pangmuang P, Seeda K, et al. National Cervical Cancer Screening in Thailand. Asian Pac J Cancer Prev. 2021;22(1):25–30.CrossRefPubMedPubMedCentral Ploysawang P, Rojanamatin J, Prapakorn S, Jamsri P, Pangmuang P, Seeda K, et al. National Cervical Cancer Screening in Thailand. Asian Pac J Cancer Prev. 2021;22(1):25–30.CrossRefPubMedPubMedCentral
7.
go back to reference Akoto EJ, Allsop MJ. Factors influencing the experience of breast and Cervical Cancer screening among women in low- and Middle-Income countries: a systematic review. JCO Glob Oncol. 2023;9:e2200359.CrossRefPubMedPubMedCentral Akoto EJ, Allsop MJ. Factors influencing the experience of breast and Cervical Cancer screening among women in low- and Middle-Income countries: a systematic review. JCO Glob Oncol. 2023;9:e2200359.CrossRefPubMedPubMedCentral
8.
go back to reference Gottschlich A, Nuntadusit T, Zarins KR, Hada M, Chooson N, Bilheem S, et al. Barriers to Cervical cancer screening and acceptability of HPV self-testing: a cross-sectional comparison between ethnic groups in Southern Thailand. BMJ Open. 2019;9(11):e031957.CrossRefPubMedPubMedCentral Gottschlich A, Nuntadusit T, Zarins KR, Hada M, Chooson N, Bilheem S, et al. Barriers to Cervical cancer screening and acceptability of HPV self-testing: a cross-sectional comparison between ethnic groups in Southern Thailand. BMJ Open. 2019;9(11):e031957.CrossRefPubMedPubMedCentral
9.
go back to reference Sy F, Greuel M, Winkler V, Bussmann H, Bärnighausen T, Deckert A. Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: a systematic review and meta-analysis. Gynecol Oncol. 2022;166(2):358–68.CrossRefPubMed Sy F, Greuel M, Winkler V, Bussmann H, Bärnighausen T, Deckert A. Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: a systematic review and meta-analysis. Gynecol Oncol. 2022;166(2):358–68.CrossRefPubMed
10.
go back to reference Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83.CrossRefPubMed Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83.CrossRefPubMed
11.
go back to reference Stewart DE, Gagliardi A, Johnston M, Howlett R, Barata P, Lewis N, et al. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynecol Canada: JOGC = J D’obstetrique et gynecologie du Can : JOGC. 2007;29(10):817–28. Stewart DE, Gagliardi A, Johnston M, Howlett R, Barata P, Lewis N, et al. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynecol Canada: JOGC = J D’obstetrique et gynecologie du Can : JOGC. 2007;29(10):817–28.
12.
go back to reference The Royal Thai College of Obstetricians and Gynaecologists. Cerv Cancer Screen. 2021:1–11 pp.]. The Royal Thai College of Obstetricians and Gynaecologists. Cerv Cancer Screen. 2021:1–11 pp.].
13.
go back to reference Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–46.CrossRefPubMed Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–46.CrossRefPubMed
14.
go back to reference Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmaco Economics. 2022;40(6):601–9.CrossRef Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmaco Economics. 2022;40(6):601–9.CrossRef
15.
go back to reference Guideline Development Working Group. Health Technology Assessment Guideline for Thailand. 3 ed. 2019. Feb 2021. Guideline Development Working Group. Health Technology Assessment Guideline for Thailand. 3 ed. 2019. Feb 2021.
16.
go back to reference Arbyn M, Latsuzbaia A, Castle PE, Sahasrabuddhe VV, Broeck DV. HPV testing of self-samples: influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. Lancet Reg Health Eur. 2022;14:100332.CrossRefPubMedPubMedCentral Arbyn M, Latsuzbaia A, Castle PE, Sahasrabuddhe VV, Broeck DV. HPV testing of self-samples: influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. Lancet Reg Health Eur. 2022;14:100332.CrossRefPubMedPubMedCentral
17.
go back to reference Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWJ, et al. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Reg Health Eur. 2021;11:100235.CrossRefPubMedPubMedCentral Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWJ, et al. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Reg Health Eur. 2021;11:100235.CrossRefPubMedPubMedCentral
18.
go back to reference Tangjitgamol S, Kantathavorn N, Kittisiam T, Chaowawanit W, Phoolcharoen N, Manusirivithaya S, et al. Prevalence and Associated factors of abnormal cervical cytology and HighRisk HPV DNA among Bangkok Metropolitan women. Asian Pac J Cancer Prev. 2016;17(7):3147–53.PubMed Tangjitgamol S, Kantathavorn N, Kittisiam T, Chaowawanit W, Phoolcharoen N, Manusirivithaya S, et al. Prevalence and Associated factors of abnormal cervical cytology and HighRisk HPV DNA among Bangkok Metropolitan women. Asian Pac J Cancer Prev. 2016;17(7):3147–53.PubMed
19.
go back to reference Phoolcharoen N, Kantathavorn N, Sricharunrat T, Saeloo S, Krongthong W. A population-based study of cervical cytology findings and human papillomavirus Infection in a suburban area of Thailand. Gynecol Oncol Rep. 2017;21:73–7.CrossRefPubMedPubMedCentral Phoolcharoen N, Kantathavorn N, Sricharunrat T, Saeloo S, Krongthong W. A population-based study of cervical cytology findings and human papillomavirus Infection in a suburban area of Thailand. Gynecol Oncol Rep. 2017;21:73–7.CrossRefPubMedPubMedCentral
20.
go back to reference Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and Cervical cancer screening in Thailand. BJOG. 2012;119(2):166–76.CrossRefPubMed Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and Cervical cancer screening in Thailand. BJOG. 2012;119(2):166–76.CrossRefPubMed
21.
go back to reference Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of Cervical cancer in Thailand. PharmacoEconomics. 2011;29(9):781–806.CrossRefPubMed Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of Cervical cancer in Thailand. PharmacoEconomics. 2011;29(9):781–806.CrossRefPubMed
22.
go back to reference Gomez-Hidalgo NR, Acosta U, Rodriguez TG, Mico S, Verges R, Conesa VB, et al. Adjuvant therapy in early-stage Cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis. Clin Transl Oncol. 2022;24(8):1605–14.CrossRefPubMed Gomez-Hidalgo NR, Acosta U, Rodriguez TG, Mico S, Verges R, Conesa VB, et al. Adjuvant therapy in early-stage Cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis. Clin Transl Oncol. 2022;24(8):1605–14.CrossRefPubMed
23.
go back to reference Bekos C, Schwameis R, Heinze G, Garner M, Grimm C, Joura E, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8(1):6383.CrossRefPubMedPubMedCentral Bekos C, Schwameis R, Heinze G, Garner M, Grimm C, Joura E, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8(1):6383.CrossRefPubMedPubMedCentral
24.
go back to reference Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cardenas J, Hernandes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.CrossRefPubMedPubMedCentral Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cardenas J, Hernandes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.CrossRefPubMedPubMedCentral
25.
go back to reference Xue R, Cai X, Xu H, Wu S, Huang H. The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of Cervical cancer: a meta-analysis. Gynecol Oncol. 2018;150(3):412–9.CrossRefPubMed Xue R, Cai X, Xu H, Wu S, Huang H. The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of Cervical cancer: a meta-analysis. Gynecol Oncol. 2018;150(3):412–9.CrossRefPubMed
26.
go back to reference Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C. Chemotherapy for metastatic and recurrent Cervical cancer. Cochrane Database Syst Rev. 2012;10(10):CD006469.PubMed Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C. Chemotherapy for metastatic and recurrent Cervical cancer. Cochrane Database Syst Rev. 2012;10(10):CD006469.PubMed
28.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.
30.
31.
go back to reference Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006.CrossRef Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006.CrossRef
32.
go back to reference Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai. 2008;91(Suppl2):59–S65. Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai. 2008;91(Suppl2):59–S65.
33.
go back to reference Intharaburan S, Rakdang I, Tanapat Y. Colposcopic directed biopsy in the management of abnormal pap smear at Phramongkutklao Hospital. J Med Assoc Thai. 2005;88(Suppl 3):14–8. Intharaburan S, Rakdang I, Tanapat Y. Colposcopic directed biopsy in the management of abnormal pap smear at Phramongkutklao Hospital. J Med Assoc Thai. 2005;88(Suppl 3):14–8.
35.
go back to reference Ministry of Public Health, National Cancer Institute. Cancer in Thailand Vol X, 2016–8. 2021. Ministry of Public Health, National Cancer Institute. Cancer in Thailand Vol X, 2016–8. 2021.
36.
go back to reference Termrungruanglert W, Khemapech N, Tantitamit T, Sangrajrang S, Havanond P, Laowahutanont P. Cost-effectiveness analysis study of HPV testing as a primary Cervical cancer screening in Thailand. Gynecol Oncol Rep. 2017;22:58–63.CrossRefPubMedPubMedCentral Termrungruanglert W, Khemapech N, Tantitamit T, Sangrajrang S, Havanond P, Laowahutanont P. Cost-effectiveness analysis study of HPV testing as a primary Cervical cancer screening in Thailand. Gynecol Oncol Rep. 2017;22:58–63.CrossRefPubMedPubMedCentral
37.
go back to reference Parker SL, Deshmukh AA, Chen B, Lairson DR, Daheri M, Vernon SW et al. Perceived barriers to Cervical cancer screening and motivators for at-home human papillomavirus self-sampling during the COVID-19 pandemic: results from a telephone survey. Elife. 2023;12. Parker SL, Deshmukh AA, Chen B, Lairson DR, Daheri M, Vernon SW et al. Perceived barriers to Cervical cancer screening and motivators for at-home human papillomavirus self-sampling during the COVID-19 pandemic: results from a telephone survey. Elife. 2023;12.
38.
go back to reference Vassilakos P, Poncet A, Catarino R, Viviano M, Petignat P, Combescure C. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in Cervical cancer screening in Switzerland. Gynecol Oncol. 2019;153(1):92–9.CrossRefPubMed Vassilakos P, Poncet A, Catarino R, Viviano M, Petignat P, Combescure C. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in Cervical cancer screening in Switzerland. Gynecol Oncol. 2019;153(1):92–9.CrossRefPubMed
39.
go back to reference Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of Cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017;141(3):437–46.CrossRefPubMed Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of Cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017;141(3):437–46.CrossRefPubMed
40.
go back to reference Trope LA, Chumworathayi B, Blumenthal PD. Preventing Cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-Et Province, Thailand. Int J Gynecol Cancer. 2009;19(8):1432–8.CrossRefPubMed Trope LA, Chumworathayi B, Blumenthal PD. Preventing Cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-Et Province, Thailand. Int J Gynecol Cancer. 2009;19(8):1432–8.CrossRefPubMed
41.
go back to reference Saidu R, Moodley J, Tergas A, Momberg M, Boa R, Wright T, et al. South African women’s perspectives on self-sampling for Cervical cancer screening: a mixed-methods study. S Afr Med J. 2018;109(1):47–52.CrossRefPubMed Saidu R, Moodley J, Tergas A, Momberg M, Boa R, Wright T, et al. South African women’s perspectives on self-sampling for Cervical cancer screening: a mixed-methods study. S Afr Med J. 2018;109(1):47–52.CrossRefPubMed
42.
go back to reference Campos NG, Alfaro K, Maza M, Sy S, Melendez M, Masch R, et al. The cost-effectiveness of human papillomavirus self-collection among Cervical cancer screening non-attenders in El Salvador. Prev Med. 2020;131:105931.CrossRefPubMed Campos NG, Alfaro K, Maza M, Sy S, Melendez M, Masch R, et al. The cost-effectiveness of human papillomavirus self-collection among Cervical cancer screening non-attenders in El Salvador. Prev Med. 2020;131:105931.CrossRefPubMed
Metadata
Title
Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand
Authors
Chayanis Kositamongkol
Sukrit Kanchanasurakit
Euarat Mepramoon
Pattarawalai Talungchit
Pattama Chaopotong
Kirati Kengkla
Thanet Chaisathaphol
Surasak Saokaew
Pochamana Phisalprapa
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2023
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-023-17358-0

Other articles of this Issue 1/2023

BMC Public Health 1/2023 Go to the issue